Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	160003-66-7
Formula :	C₇H₅IN₂O₃
M.W :	292.03
SMILES Code :	IC1=C(C=C(C(=O)N)C=C1)[N+](=O)[O-]
Synonyms :	BSI-201; IND-71677; SAR-240550
MDL No. :	MFCD11110639
InChI Key :	MDOJTZQKHMAPBK-UHFFFAOYSA-N
Pubchem ID :	9796068

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H319
Precautionary Statements:	P305+P351+P338

LCL35 cells	100 μM	2 hours	Evaluate the effect of Iniparib on the repair of radiation-induced single-strand breaks, showing that Iniparib inhibited SSB repair, but PARP1 knockdown reversed this inhibition	PMC3340099
Raji cells	100 μM	2 hours	Evaluate the effect of Iniparib on the repair of radiation-induced single-strand breaks, showing that Iniparib inhibited SSB repair	PMC3340099
HepG2 cells	10, 20, 40, 60, 80 μM	24, 48, 72, 96 h	BSI-201 inhibited the proliferation of HepG2 cells in a time- and concentration-dependent manner.	PMC5482153
HepG2 cells	50, 100, 200, 400, 800 μM	24, 48, 72, 96 h	AZD2281 inhibited the proliferation of HepG2 cells in a time- and concentration-dependent manner.	PMC5482153
HepG2 cells	5, 10, 20, 40, 80 μM	24, 48, 72, 96 h	AG014699 inhibited the proliferation of HepG2 cells in a time- and concentration-dependent manner.	PMC5482153
HCC-1428	2 µM	4 days	Evaluate the effects of PARP inhibitors on BRCA mutant cell lines, BSI-201 did not induce cell death at 2 µM	PMC6904111
SUM-149PT	2 µM	4 days	Evaluate the effects of PARP inhibitors on BRCA mutant cell lines, BSI-201 did not induce cell death at 2 µM	PMC6904111
MDA-MB-436	2 µM	4 days	Evaluate the effects of PARP inhibitors on BRCA mutant cell lines, BSI-201 did not induce cell death at 2 µM	PMC6904111
HCC-1937	2 µM	4 days	Evaluate the effects of PARP inhibitors on BRCA mutant cell lines, BSI-201 did not induce cell death at 2 µM	PMC6904111
MDA-MB-231	50 μM	48 hours	To evaluate the therapeutic effect of Iniparib on MDA-MB-231 cells, results showed sensitivity to iniparib plus cisplatin but resistance to iniparib alone, cisplatin, paclitaxel, and docetaxel.	PMC5560738
MDA-MB-468	50 μM	48 hours	To evaluate the therapeutic effect of Iniparib on MDA-MB-468 cells, results showed resistance to iniparib plus cisplatin, iniparib alone, cisplatin, paclitaxel, and docetaxel.	PMC5560738
Human NDUFS1 mutant fibroblasts	100nM	48 hours	MRL-45696 increased NAD+ levels and oxygen consumption rate, improving mitochondrial function	PMC4047186
MCF-7 cells	50 μM	48 hrs	To evaluate the effect of ATM-depletion on MCF-7 cell sensitivity to iniparib, results showed G2/M phase accumulation.	PMC4176289
GM16667 human fibroblasts	80 µM	6 days	Evaluate the selective cytotoxicity of Iniparib in ATM-proficient cells, results showed Iniparib had low selectivity for GM16667 cells	PMC3306513
GM16666 human fibroblasts	80 µM	6 days	Evaluate the selective cytotoxicity of Iniparib in ATM-deficient cells, results showed Iniparib had low selectivity for GM16666 cells	PMC3306513
PEO4 human ovarian cancer cells	80 µM	6 days	Evaluate the selective cytotoxicity of Iniparib in HR-proficient cells, results showed Iniparib had low selectivity for PEO4 cells	PMC3306513
PEO1 human ovarian cancer cells	80 µM	6 days	Evaluate the selective cytotoxicity of Iniparib in HR-deficient cells, results showed Iniparib had low selectivity for PEO1 cells	PMC3306513
Primary myotubes from obese patients	10 nM	72 hours	MRL-45696 increased NAD+ levels and oxygen consumption rate, improving mitochondrial function	PMC4047186
ZR-75-1 cells	100 μM	72 hrs	To evaluate the effect of ATM-depletion on ZR-75-1 cell sensitivity to iniparib, results showed no effect of ATM-depletion on sensitivity.	PMC4176289
SKOV3 human ovarian cancer cells	10 µM	continuously	Evaluate the sensitization effect of Iniparib to topoisomerase I poisons, results showed Iniparib failed to sensitize SKOV3 cells to topotecan	PMC3306513
C2C12 myotubes	1–10 nM		MRL-45696 reduced redox potential, increased mitochondrial membrane potential and oxygen consumption rate	PMC4047186

Nude mice	SCC1 (head and neck cancer) or MDA-MB-231 (triple-negative breast cancer) xenografts	Intraperitoneal injection	50 mg/kg	Single dose	To evaluate the effect of iniparib on PARP activity. Results showed that iniparib had no significant effect on PARP activity and had a less marked effect on reducing 18F-FTT uptake compared to olaparib.	PMC5283874
Mice	High-fat diet-induced obesity model	Dietary admixture	50 mg/kg/day	Once daily for 18 weeks	MRL-45696 reduced high-fat diet-induced weight gain and fat accumulation, increased energy expenditure, and improved mitochondrial function	PMC4047186

{[proInfo.proName]}

CAS No.: 160003-66-7

{[proInfo.proName]}

CAS No.: 160003-66-7

Alternative Products

Product Details of Iniparib

Safety of Iniparib

Related Pathways of Iniparib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01593228	Solid Tumors	Phase 3	Completed	-	-
NCT01455532	Neoplasm Malignant	Phase 1	Completed	-	United States, Arizona ... More >> Investigational Site Number 840002 Scottsdale, Arizona, United States, 85258 United States, California Investigational Site Number 840004 Los Angeles, California, United States, 90048 United States, Georgia Investigational Site Number 840010 Augusta, Georgia, United States, 30912 United States, Missouri Investigational Site Number 840007 St Louis, Missouri, United States, 63110 United States, Ohio Investigational Site Number 840001 Cincinnati, Ohio, United States, 45267-0542 United States, Texas Investigational Site Number 840006 San Antonio, Texas, United States, 78229 Less <<
NCT00813956	Triple Negative Breast Cancer	Phase 2	Completed	-	United States, California ... More >> Stanford Comprehensive Cancer Center Stanford, California, United States, 94305 United States, Pennsylvania PrECOG Philadelphia, Pennsylvania, United States, 19103 Less <<
NCT01204125	Breast Cancer Female	Phase 2	Completed	-	France ... More >> Investigational Site Number 250001 Besancon Cedex, France, 25030 Investigational Site Number 250004 Bordeaux, France, 33076 Investigational Site Number 250006 Bron Cedex, France, 69677 Investigational Site Number 250003 Paris Cedex 10, France, 75475 Investigational Site Number 250002 Toulouse, France, 31052 Investigational Site Number 250005 Villejuif, France, 94805 Germany Investigational Site Number 276003 Erlangen, Germany, 91054 Investigational Site Number 276004 Hamburg, Germany, 20357 Investigational Site Number 276002 Köln, Germany, 50931 Investigational Site Number 276001 Mönchengladbach, Germany, 41061 Spain Investigational Site Number 724001 Barcelona, Spain, 08035 Investigational Site Number 724009 Cáceres, Spain, 10003 Investigational Site Number 724013 Córdoba, Spain, 14004 Investigational Site Number 724006 Islas Baleares, Spain, 07014 Investigational Site Number 724012 Jaén, Spain, 23007 Investigational Site Number 724002 Lérida, Spain, 25198 Investigational Site Number 724005 Madrid, Spain, 28033 Investigational Site Number 724016 Madrid, Spain, 28041 Investigational Site Number 724007 Reus, Spain, 43201 Investigational Site Number 724018 Santiago De Compostela, Spain, 15706 Investigational Site Number 724017 Sevilla, Spain, 41009 Investigational Site Number 724010 Sevilla, Spain, 41013 Investigational Site Number 724003 Torrevieja, Spain, 03186 Investigational Site Number 724011 Valencia, Spain, 46009 Investigational Site Number 724015 Valencia, Spain, 46010 Less <<
NCT01173497	Estrogen Receptor Negative (ER... More >>-Negative) Breast Cancer Progesterone Receptor Negative (PR-Negative) Breast Cancer Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer Brain Metastases Less <<	Phase 2	Completed	-	United States, Alabama ... More >> University of Alabama At Birmingham Birmingham, Alabama, United States United States, California University of California At San Francisco San Francisco, California, United States United States, District of Columbia Georgetown University Washington, District of Columbia, United States United States, Illinois University of Chicago Chicago, Illinois, United States United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States United States, Maryland Johns Hopkins University Baltimore, Maryland, United States United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States United States, Michigan University of Michigan Ann Arbor, Michigan, United States United States, North Carolina University of North Carolina-CH Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599-7295 Duke University Durham, North Carolina, United States United States, Pennsylvania University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States United States, Tennessee Vanderbilt University Nashville, Tennessee, United States United States, Texas MD Anderson Cancer Center Houston, Texas, United States Less <<
NCT01213381	Advance Solid Tumors	Phase 1	Completed	-	Japan ... More >> Sanofi-Aventis Investigational Site Number 392001 Kobe-Shi, Japan Sanofi-Aventis Investigational Site Number 392002 Matsuyama-Shi, Japan Less <<
NCT00422682	Tumors	Phase 1	Completed	-	United States, Connecticut ... More >> Research Site New Haven, Connecticut, United States United States, Michigan Research Site Detroit, Michigan, United States United States, New York Research Site New York City, New York, United States United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States United States, Texas Research Site Houston, Texas, United States Research Site San Antonio, Texas, United States Less <<
NCT01130259	-		-	-	-
NCT01086254	Non-small Cell Lung Cancer Sta... More >>ge IV Less <<	Phase 2	Completed	-	France ... More >> Sanofi-Aventis Investigational Site Number 250002 Caen Cedex, France, 14033 Sanofi-Aventis Investigational Site Number 250003 Marseille Cedex 09, France, 13009 Sanofi-Aventis Investigational Site Number 250004 Toulouse, France, 31059 Sanofi-Aventis Investigational Site Number 250001 Villejuif, France, 94805 Germany Sanofi-Aventis Investigational Site Number 276003 Essen, Germany, 45122 Sanofi-Aventis Investigational Site Number 276002 Gauting, Germany, 82131 Sanofi-Aventis Investigational Site Number 276001 Großhansdorf, Germany, 22927 Italy Sanofi-Aventis Investigational Site Number 380003 Livorno, Italy, 57123 Sanofi-Aventis Investigational Site Number 380001 Orbassano, Italy, 10043 Sanofi-Aventis Investigational Site Number 380002 Rozzano, Italy, 20089 Spain Sanofi-Aventis Investigational Site Number 724001 Badalona, Spain, 08916 Sanofi-Aventis Investigational Site Number 724002 Barcelona, Spain, 08035 United Kingdom Sanofi-Aventis Investigational Site Number 826001 Newcastle Upon Tyne, United Kingdom, NE7 7DN Sanofi-Aventis Investigational Site Number 826002 Wolverhampton, United Kingdom, WV10 0QP Less <<
NCT00540358	Breast Cancer	Phase 2	Completed	-	United States, Alabama ... More >> Research Site Birmingham, Alabama, United States United States, Colorado Research Site Denver, Colorado, United States United States, Connecticut Research Site Torrington, Connecticut, United States United States, Florida Research Site Ocoee, Florida, United States United States, Indiana Research Site Indianapolis, Indiana, United States United States, Kansas Research Site Overland Park, Kansas, United States United States, Nevada Research Site Henderson, Nevada, United States United States, New Hampshire Research Site Hooksett, New Hampshire, United States United States, North Carolina Research Site Raleigh, North Carolina, United States United States, Texas Research Site Bedford, Texas, United States Research Site Dallas, Texas, United States Research Site El Paso, Texas, United States Research Site Fort Worth, Texas, United States Research Site Houston, Texas, United States Research Site Tyler, Texas, United States United States, Virginia Research Site Fairfax, Virginia, United States United States, Washington Research Site Vancouver, Washington, United States Research Site Yakima, Washington, United States Less <<
NCT00938652	Breast Cancer	Phase 3	Completed	-	-
NCT00298675	Tumors	Phase 1	Completed	-	United States, Connecticut ... More >> Research Site New Haven, Connecticut, United States United States, Texas Research Site Houston, Texas, United States Research Site San Antonio, Texas, United States Less <<
NCT01045304	Breast Cancer, Metastatic	Phase 2	Completed	-	Australia ... More >> Sanofi-Aventis Investigational Site Number 036002 Parkville, Australia, 3052 Sanofi-Aventis Investigational Site Number 036001 Perth, Australia, 6000 Sanofi-Aventis Investigational Site Number 036003 Westmead, Australia, 2145 Belgium Sanofi-Aventis Investigational Site Number 056001 Bruxelles, Belgium, 1000 Sanofi-Aventis Investigational Site Number 056002 Leuven, Belgium, 3000 France Sanofi-Aventis Investigational Site Number 250005 Besancon Cedex, France, 25030 Sanofi-Aventis Investigational Site Number 250003 Bordeaux, France, 33076 Sanofi-Aventis Investigational Site Number 250002 Dijon, France, 21034 Sanofi-Aventis Investigational Site Number 250006 Paris Cedex 05, France, 75231 Sanofi-Aventis Investigational Site Number 250004 Paris, France, 75970 Sanofi-Aventis Investigational Site Number 250001 Toulouse, France, 31052 Italy Sanofi-Aventis Investigational Site Number 380004 Genova, Italy, 16132 Sanofi-Aventis Investigational Site Number 380001 Milano, Italy, 20133 Sanofi-Aventis Investigational Site Number 380002 Modena, Italy, 41100 Sanofi-Aventis Investigational Site Number 380003 Udine, Italy, 33100 Netherlands Sanofi-Aventis Investigational Site Number 528001 Rotterdam, Netherlands, 3075 EA Spain Sanofi-Aventis Investigational Site Number 724002 Barcelona, Spain, 08035 Sanofi-Aventis Investigational Site Number 724004 Madrid, Spain, 28050 Sanofi-Aventis Investigational Site Number 724001 Málaga, Spain, 29010 Sanofi-Aventis Investigational Site Number 724003 Valencia, Spain, 46010 Less <<
NCT01082549	Squamous Cell Lung Cancer	Phase 3	Completed	-	-
NCT00677079	Primary Peritoneal Cancer\|Adva... More >>nced Epithelial Ovarian Cancer Less <<	PHASE2	COMPLETED	2025-12-08	New York, New York, 10021, Uni... More >>ted States Less <<
NCT00687765	Glioblastoma	Phase 1 Phase 2	Completed	-	United States, Alabama ... More >> Research Site Birmingham, Alabama, United States, 35294 United States, Florida Research Site Tampa, Florida, United States, 33612 United States, Georgia Research Site Atlanta, Georgia, United States, 30322 United States, Maryland Research Site Baltimore, Maryland, United States United States, Massachusetts Research Site Boston, Massachusetts, United States, 92114 United States, Michigan Research Site Detroit, Michigan, United States, 48202 United States, North Carolina Research Site Winston Salem, North Carolina, United States, 27157 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01161836	Advanced Solid Tumors	PHASE1	COMPLETED	2025-06-11	Northwest Medical Specialties,... More >> Tacoma, Washington, 98405, United States Less <<
NCT01033123	Ovarian Cancer	PHASE2	COMPLETED	2025-02-12	Massachusetts Ceneral Hospital... More >>, Boston, Massachusetts, 02114, United States Less <<
NCT01551680	Brain Metastases	Phase 1	Terminated(end of study of thi... More >>s product) Less <<	-	France ... More >> CRLC Val d'Aurelle-Paul Lamarque Montpellier, France, 34298 AP-HP Hôpital Saint-Louis Paris, France Institut Gustave-Roussy Villejuif, France Less <<
NCT01033292	Ovarian Cancer	PHASE2	COMPLETED	2025-12-12	Massachusetts Ceneral Hospital... More >>, Boston, Massachusetts, 02114, United States Less <<
NCT00687687	Uterine Carcinosarcoma	Phase 2	Completed	-	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed